| Authors: |
Demarest JF; INTREPID Alliance, Cambridge, MA, USA., Draghia-Akli R; INTREPID Alliance, Cambridge, MA, USA., Cihlar T; INTREPID Alliance, Cambridge, MA, USA.; Gilead Sciences, Foster City, CA, USA., Bradley K; INTREPID Alliance, Cambridge, MA, USA.; Roche pharmaceutical Research and Early Development (pRED), Basel, Switzerland., Young JAT; INTREPID Alliance, Cambridge, MA, USA.; Roche pharmaceutical Research and Early Development (pRED), Basel, Switzerland., Chandra R; Novartis Pharmaceuticals, East Hanover, NJ, USA., Vaidyanathan S; Novartis Pharmaceuticals, East Hanover, NJ, USA., Chu-Moyer M; Amgen, Thousand Oaks, CA, USA., Lynch CL; AbbVie, North Chicago, IL, USA., Campbell A; AbbVie, North Chicago, IL, USA., Saikatendu KS; Takeda, San Diego, CA, USA., Bilello JP; Gilead Sciences, Foster City, CA, USA., Murata Y; Gilead Sciences, Foster City, CA, USA., van Loock M; Janssen Pharmaceutica NV, a Johnson & Johnson company, Beerse, Belgium., Hurt AC; F. Hoffmann-La Roche Ltd, Basel, Switzerland., Tellinghuisen T; Roche pharmaceutical Research and Early Development (pRED), Basel, Switzerland., Ruggiero L; INTREPID Alliance, Cambridge, MA, USA., Mackman R; INTREPID Alliance, Cambridge, MA, USA., Hill NM; INTREPID Alliance, Cambridge, MA, USA., Pottage JC Jr; INTREPID Alliance, Cambridge, MA, USA. john.pottagemd@gmail.com. |
